Next steps: FDA decision (REDEFINE-1 & 2) expected late 2026 REDEFINE-11 (2.4/2.4 mg) readout in H1 2027 Higher-dose Phase 3 initiation planned H2 2026 Why It Matters: The obesity market is now a high-efficacy battleground, with GLP-1 and dual incretin therapies redefining standards of care
DOI: 10.1002/ctm2.1232 [Google Scholar] Pattison LA, Rickman RH, Hilton H, Dannawi M, Wijesinghe SN, Ladds G, et al
However, no randomized controlled trials have tested whether adding glutathione to GLP-1 therapy improves outcomes beyond semaglutide alone
However, if you are seeking weight loss support or muscle recovery, you can take the benefits of the supplement by consuming it after exercise
The third pillar of GLP-1 action targets your reward system
Increased Sex drive: Sex is huge